🔗 Share this article

Given that the United States undertakes unprecedented adjustments to its immunization guidelines, an unexpected name appears unexpectedly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations throughout the pandemic and has zeroed in on potential deaths after COVID-19 vaccination in her short time at the FDA.

Planned Changes to Childhood Immunization Program

Agency leaders were set to announce sweeping changes to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US at odds with a large portion of the international standard with no evidence for improved outcomes. The planned update has been delayed until the next year.

Instead of Vinay Prasad, Dr. Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and vaccine branches as Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood immunization guidelines in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious experience in drug development, regulation or leadership, which has been typical for past heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She appears not to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the research of medication creation”, said a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that former directors who headed CBER have had.”

The drug center has an vast range of responsibilities at the FDA, she stated.

“Everybody just pays attention on the new drug program, but the off-patent medication office clears thousands of generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and each of these have to be looked after,” she explained. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the role, which manages in excess of 5,000 employees. “It is a huge leadership role, if you perform it correctly,” the former official said.

Official Statement and Disputed Programs

In response to questions about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among agency officials on immunizations, a spokesperson said that the “concerns rely on inaccurate assumptions”.

“This background aligns with the functions of her job,” the official said, noting the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's controversial priority voucher program, a contentious expedited drug-approval program that reportedly troubled her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards less stringent oversight of pharmaceuticals, except for immunizations.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard have noted. She published a analysis using unverified public submissions to estimate the rate of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “policy goals” for the current federal leadership included revising regulations for recently developed shots and halting “non-essential” immunizations, she said following the vote on a podcast. At the FDA, Høeg has reportedly proposed excluding young men from receiving Covid vaccinations.

“She is an all-around ideologue who begins with her beliefs and tailors the evidence to fit the data in a very misleading, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg joined other contrarians, {like|